Viatris Inc.
VTRS
NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·Mkt cap $19.9B
$17.09
▲ +2.77%
P/E
-47.47
Mkt Cap
$19.9B
52-Wk Range
$9.43–$18.39
52-Week Range
$9.43 - $18.39
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 61.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Extensive Global Distribution Network
- Diverse Pharmaceutical Portfolio
- Cost-Effective Manufacturing Capabilities
- Strong Regulatory Compliance Infrastructure
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Expanding Biosimilars Market
Value
Undervalued - trading well below Large Cap Pharma peers
Momentum
Strong
+8.9% over 3m
Quality
Stable
Excellent business quality
Dividend
Solid
2.81% yield
Smart-money signal
Who's buying VTRS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 6, 2026
Reported EPS of $0.69 vs $0.60 consensus (+14.8% surprise). Revenue of $3.8B vs $3.7B expected (+2.2%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+14.8%
Revenue trend · last 8Q
—
-8%
-11%
-6%
+0%
+5%
+8%
+5%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$3.8B
$3.5B
$3.3B
$3.6B
$3.8B
$3.7B
$3.5B
$3.8B
Margins · last 8Q
Gross
38.8%
Operating
0.2%
Profit
-3.2%
Wall Street consensus
3 analysts · 67% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
67%
Hold
33%
Sell
0%
Median Price Target
—
Latest: Barclays · $22.00 · May 19, 2026
vs Industry
How VTRS stacks vs Drug Manufacturers - Specialty & Generic
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related